Targeted radiotherapy (SFRT or SCART) for bone metastases with soft-tissue tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, controlled, prospective phase II, two-arm study enrolling 90 patients who have bone metastases with a soft-tissue mass and randomizing them 2:1 to SFRT/SCART versus conventional radiotherapy. The primary endpoint is objective response rate (ORR) of the target lesion measured by RECIST 1.1 at 3, 6, 9, and 12 months after radiotherapy. Secondary endpoints include pain relief rate, progression-free survival (PFS), and safety with adverse events monitored throughout per CTCAE v5.0. Key eligibility includes age 18–75, ECOG 0–2, a soft-tissue lesion diameter >30 mm, ≤5 metastatic lesions in ≤3 organs, expected survival ≥3 months, and no prior radiotherapy to the target lesion.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1\. Sign a written informed consent form before implementing any trial-related procedures; 2. Male or female, aged 18 years or above and 75 years or below; 3. Have a histopathologically confirmed single primary tumor (patients with a pathological diagnosis of small cell carcinoma or undifferentiated carcinoma are excluded); 4. ECOG PS 0-2; 5. Have at least one target lesion: bone metastasis with a soft tissue mass confirmed by CT or MRI. The shortest diameter of the soft tissue is greater than 30mm; 6. The number of metastatic lesions is ≤ 5 and the number of metastatic organs is ≤ 3; 7. The expected survival time is ≥ 3 months; 8. The main organ functions are normal (within 14 days before enrollment), that is, the following criteria are met:

1. The blood routine examination criteria should meet:

   1. Hemoglobin (HB) ≥ 90g/L;
   2. Absolute neutrophil count (ANC) ≥ 1.5×10⁹/L;
   3. Platelet count (PLT) ≥ 75×10⁹/L;
2. There is no functional organic disease, and the following criteria should be met:

   1. When there is no liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× ULN, serum total bilirubin ≤ 1.5× ULN, alkaline phosphatase (ALP) ≤ 3× ULN; when there is liver metastasis, ALT and AST ≤ 5× ULN, serum total bilirubin ≤ 3× ULN, and alkaline phosphatase (ALP) ≤ 5× ULN;
   2. Serum creatinine level Cr ≤ 1.5×ULN (if the serum creatinine is elevated, a 24-hour urine collection is required, except for those with a 24-hour creatinine clearance rate \> 50ml/min);
   3. Urine protein \< 2+. If the test strip result is ≥ 2+, the 24-hour urine protein must be \< 2g, or the urine protein-to-creatinine ratio (UPC) must be \< 2;
   4. International normalized ratio (INR) and activated partial thromboplastin time (APTT): ≤ 1.5×ULN;

Exclusion Criteria:

1. Pathological fracture confirmed by CT or MR.
2. Prior radiotherapy to the target lesion.
3. Pregnant or lactating women.
4. Acute infection or other serious underlying diseases.
5. Obvious history of neurological and mental diseases, including dementia that may affect the ability to understand and give informed consent.
6. History or evidence of diseases, treatments or abnormal laboratory test values that may interfere with the test results and prevent the subject from participating in the study throughout the whole process, or other situations that the researcher deems inappropriate for enrollment. The researcher believes that there are other potential risks that make the subject unsuitable for participating in this study.

Where it's running

• Shandong Cancer Hospital and Institute
  Jinan, Shandong, China Recruiting

Study contacts

• Principal investigator: Jinbo Yue, Doctor — Shandong Cancer Hospital and Institute
• Study coordinator: Jinbo Yue, Doctor
• Email: jbyue@sdfmu.edu.cn
• Phone: 0531-67626442

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Samarium-153 treatment optimized for longer-lasting relief of end-stage cancer bone pain

  This trial will test a samarium-153 radioligand injection to see if it reduces severe bone pain in adults with advanced cancer and painful bone metastases.

  Recruiting at 6 sites Phase 1 Telix Pharmaceuticals (Innovations) Pty Limited · Miami, Florida and 5 other locations · NCT07197645

• Optimizing radioactive seed implantation for spinal and bone metastases with combined treatment planning and biomechanical simulation

  This trial tries adding patient-specific biomechanical simulation to standard treatment planning to see if radioactive seed implantation gives better pain control and fewer complications for adults with painful or progressive bone metastases.

  Recruiting Jinan Military General Hospital · Jinan, Shandong · NCT07171996

• Early palliative care consultation for people with bone metastases referred for radiotherapy

  This trial will test if offering an early hospital palliative care consultation improves quality of life and satisfaction for adults with advanced cancer and bone metastases who are referred for palliative radiotherapy.

  Recruiting at 5 sites Phase 2 UMC Utrecht · Amersfoort and 4 other locations · NCT06805396

• Treatment for advanced breast cancer using RYZ101

  This study is testing a new treatment called RYZ101 for people with advanced breast cancer that can't be removed by surgery to see if it helps manage their condition.

  Recruiting Phase 1/2 RayzeBio, Inc. · Phoenix, Arizona and 30 other locations · NCT06590857

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.